PCI Biotech Holding ASA publishes the Annual Report 2021
Oslo, Norway, April 28, 2022
The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2021 and the report is attached, in addition to the report according to the European Single Electronic Format (ESEF). The Annual Report 2021 is also available on the company’s website www.pcibiotech.com.
For further information, please contact:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO, email@example.com, Mobile: +47 917 93 429
Ronny Skuggedal, CFO, firstname.lastname@example.org, Mobile: +47 940 05 757
About PCI Biotech
PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.
The company’s lead programme fimaVacc aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through an extensive Phase I study in healthy volunteers and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Statkraft and FREYR Battery Sign Agreement, Securing Long-Term Supply of Renewable Energy25.5.2022 10:01:21 CEST | Press release
(New York, Oslo and Luxembourg, May 25, 2022) Statkraft, Europe’s largest producer of renewable energy has signed a binding Heads of Terms with FREYR Battery (NYSE: FREY) (“FREYR”), a developer of clean, next-generation battery cell production capacity. The Heads of Terms is expected to be finalized as a long-term physical supply agreement, with the ambition to secure a long-term supply of renewable power under globally competitive terms for FREYR’s planned battery cell production project in Mo i Rana, Norway. The Heads of Terms and related energy services from Statkraft is projected to cover all of FREYR’s currently anticipated electricity needs for the period of 2024-2031 and to ensure physical delivery of energy from the central grid in Mo i Rana to FREYR’s Customer Qualification Plant (“CQP”) and combined Gigafactory 1 & 2. During this period, Statkraft commits to providing up to 23 MW baseload with an accumulated delivery of 1.4 TWh over the contract period to FREYR, as well as th
Statkraft inngår avtale med FREYR Battery for langsiktig forsyning av fornybar energi25.5.2022 10:01:21 CEST | Pressemelding
(New York, Oslo og Luxembourg, 25. mai 2022) Statkraft, Europas største produsent av fornybar energi har inngått en bindende prinsippavtale med FREYR Battery (NYSE: FREY) (“FREYR”), en utvikler av ren, neste-generasjons produksjonskapasitet for battericeller. Prinsippavtalen ventes å bli ferdigstilt som en langsiktig kraftkjøpsavtale (PPA), med sikte på å sikre langsiktig forsyning av fornybar energi til globalt konkurransedyktige vilkår for FREYRs planlagte battericellefabrikker i Mo i Rana, Norge. Avtalen og tilknyttede energitjenester levert av Statkraft, anslås å dekke hele det forventede strømbehovet i perioden 2024-2031 og sikre fysisk leveranse av kraft fra sentralnettet i Mo i Rana til FREYRs pilotfabrikk og den første planlagte gigafabrikken. Statkraft forplikter seg til å levere inntil 23 MW grunnlast med et samlet volum i kontraktsperioden på 1,4 TWh, sammen med opprinnelsesgarantier som dokumenterer at kraften kommer fra Statkrafts vannkraftproduksjon i regionen. - Vår ambi
ArcelorMittal launches XCarb™ Accelerator Programme to support breakthrough technology start-ups and drive decarbonisation25.5.2022 10:00:00 CEST | Press release
25May 2022 ArcelorMittal has today launched its search for the best companies and brightest ideas focused on breakthrough technologies which hold the potential to accelerate the decarbonisation of the steel industry. Breakthrough technology start-ups worldwide are invited to submit applications to compete for investment from ArcelorMittal’s XCarb™ Innovation Fund, which aims to invest up to US$100 million annually in such transformative technologies, and access to ArcelorMittal’s advice and expertise in innovation, research and development, technology commercialisation and business mentorship. Aligned with ArcelorMittal’s purpose, ‘Smarter steels for people and planet’, the XCarb™ Innovation Fund invests in companies with the potential to accelerate the transition to low, and ultimately zero, carbon emissions steelmaking, enabling them to develop more quickly and achieve the scale needed for their technologies to become commercially viable. This year, finalists will be invited to pitch
Vapers deliver an open letter to Swedish Members of the Parliament and ask to stop the vaping flavour ban25.5.2022 09:10:17 CEST | Press release
Stockholm, Sweden, May 25, 2022 (GLOBE NEWSWIRE) -- Yesterday, the global vaping advocacy group World Vapers Alliance delivered an open letter to the Swedish parliament urging policymakers to stop the flavour ban. World Vapers’ Alliance held another protest today to stand against the ban on vape flavours. The group marched in front of the Parliament with the slogan “Flavours help smokers quit” during parliament's session and delivered an open letter to members of parliament to urge them to vote against the ban. Earlier this year, the Swedish government introduced a bill that would prohibit all non-tobacco vape flavours in nicotine and non-nicotine products. If approved, the bill is set to enter into force on 1 January 2023. “I benefited first hand from vaping and managed to stay smoke free for the last few years. Like most other smokers, I tried to find a way out of cigarettes - but nothing worked for me, the patches, the gums, the inhalers. Vaping - and especially combined with flavou
Kalera - Last day of trading in Kalera AS' shares on Euronext Growth Oslo25.5.2022 08:00:00 CEST | Press release
OSLO, Norway, May 25, 2022 (GLOBE NEWSWIRE) -- Reference is made to the stock exchange announcement published by Kalera AS (the "Company") (Euronext Growth Oslo: KAL, Bloomberg: KSLLF) on 13 May 2022 regarding the merger with its wholly-owned Luxembourg subsidiary Kalera S.A. (the "Merger"). The Merger will become effective upon publication of the minutes from Kalera S.A.'s general meeting approving the Merger in accordance with Luxembourg law. Such publication, and the effectiveness of the Merger, is expected to occur on 27 May 2022 (the "Effectiveness"). The last day of trading in the Company's shares on Euronext Growth Oslo is today, 25 May 2022. A trading suspension will be imposed by the Oslo Stock Exchange following end of trading today, and the trading suspension will remain in force until the Effectiveness. As of the Effectiveness, all of the Company's assets, rights and liabilities will be transferred to Kalera S.A., and the Company will be dissolved and have it shares deliste